Table 3.
Distribution of RASSF1A promoter methylation by clinicopathological classifications and protein expression in ESCC and GCA tissues
| Classification |
ESCC (n=143) |
GCA (n=92) |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
N |
Methylated |
Unmethylated |
P |
OR |
(95%CI) |
N |
Methylated |
Unmethylated |
P |
OR |
(95%CI) |
|||||||
| n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | |||||||
|
Gender |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Male |
82 |
(57) |
43 |
(52) |
39 |
(48) |
|
|
|
58 |
(63) |
37 |
(64) |
21 |
(36) |
|
|
|
|
Female |
61 |
(43) |
33 |
(54) |
28 |
(46) |
0.84 |
0.94 |
(0.48–1.82) |
34 |
(37 |
23 |
(68) |
11 |
(32) |
0.71 |
0.84 |
(0.34–2.07) |
|
Age (y) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
≤50 |
25 |
(17) |
13 |
(52) |
12 |
(48) |
|
|
|
21 |
(23) |
16 |
(76) |
5 |
(24) |
|
|
|
|
50–60 |
48 |
(34) |
37 |
(77) |
11 |
(23) |
0.03 |
3.11 |
(1.10–8.73) |
32 |
(35) |
19 |
(59) |
13 |
(41) |
0.21 |
0.46 |
(0.13–1.56) |
|
>60 |
70 |
(49) |
26 |
(37) |
44 |
(63) |
0.20 |
0.55 |
(0.22–1.37) |
39 |
(42) |
25 |
(64) |
14 |
(36) |
0.34 |
0.56 |
(0.17–1.85) |
|
Gross pathologic classificationΦ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
1 |
38 |
(27) |
18 |
(47) |
20 |
(53) |
|
|
|
17 |
(18) |
10 |
(59) |
7 |
(41) |
|
|
|
|
2 |
25 |
(17) |
16 |
(64) |
9 |
(36) |
0.58 |
0.74 |
(0.25–2.20) |
32 |
(34) |
24 |
(67) |
8 |
(33) |
0.25 |
2.10 |
(0.60–7.36) |
|
3 |
29 |
(20) |
19 |
(66) |
10 |
(34) |
0.91 |
0.92 |
(0.23–3.77) |
33 |
(36) |
21 |
(64) |
12 |
(36) |
0.74 |
1.23 |
(0.37–4.06) |
|
4 |
19 |
(13) |
15 |
(79) |
4 |
(31) |
0.06 |
0.39 |
(0.14–1.05) |
ND |
ND |
ND |
ND |
ND |
ND |
|
|
|
|
Unclear |
32 |
(22) |
8 |
(25) |
24 |
(75) |
|
|
|
10 |
(11) |
5 |
(50) |
5 |
(50) |
|
|
|
|
Differentiation classification |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
High |
32 |
(22) |
22 |
(69) |
10 |
(31) |
|
|
|
20 |
(22) |
14 |
(70) |
6 |
(30) |
|
|
|
|
Middle |
70 |
(49) |
27 |
(39) |
43 |
(61) |
0.006 |
0.28 |
(0.12–0.69) |
31 |
(34) |
22 |
(71) |
9 |
(29) |
0.94 |
1.05 |
(0.31–3.59) |
|
Low |
34 |
(24) |
26 |
(76) |
8 |
(24) |
0.48 |
1.48 |
(0.50–4.39) |
41 |
(45) |
24 |
(59) |
17 |
(41) |
0.39 |
0.61 |
(0.19–1.89) |
|
Unclear |
7 |
(5) |
1 |
(14) |
6 |
(86) |
|
|
|
ND |
ND |
ND |
ND |
ND |
ND |
|
|
|
|
Tumor stage (T) classification |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
T1+T2 |
25 |
(17) |
13 |
(52) |
12 |
(48) |
|
|
|
14 |
(15) |
9 |
(64) |
5 |
(36) |
|
|
|
|
T3+T4 |
113 |
(79) |
62 |
(55) |
51 |
(45) |
0.38 |
1.38 |
(0.68–2.82) |
78 |
(85) |
51 |
(65) |
27 |
(35) |
0.77 |
1.20 |
(0.36–4.04) |
|
Unclear |
5 |
(3) |
2 |
(40) |
3 |
(60) |
|
|
|
ND▲ |
ND |
ND |
ND |
ND |
ND |
|
|
|
|
Tumor stage (N) classification |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
N0 |
91 |
(64) |
48 |
(53) |
43 |
(47) |
|
|
|
44 |
(48) |
28 |
(64) |
16 |
(36) |
|
|
|
|
N1 |
47 |
(33) |
27 |
(57) |
20 |
(43) |
0.60 |
1.21 |
(0.60–2.46) |
48 |
(52) |
32 |
(67) |
16 |
(33) |
0.76 |
1.143 |
(0.48–2.70) |
|
Unclear |
5 |
(3) |
1 |
(20) |
4 |
(80) |
|
|
|
ND |
ND |
ND |
ND |
ND |
ND |
|
|
|
|
Tumor stage (TNM) classification |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
I+II |
91 |
(64) |
47 |
(52) |
44 |
(48) |
|
|
|
47 |
(51) |
30 |
(64) |
17 |
(36) |
|
|
|
|
III+IV |
47 |
(33) |
28 |
(60) |
19 |
(40) |
0.38 |
1.38 |
(0.68–2.82) |
45 |
(49) |
30 |
(67) |
15 |
(33) |
0.78 |
1.13 |
(0.48–2.68) |
|
Unclear |
5 |
(3) |
1 |
(20) |
4 |
(80) |
|
|
|
ND |
ND |
ND |
ND |
ND |
ND |
|
|
|
|
RASSF1A protein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
positive |
17 |
(63) |
6 |
(35) |
11 |
(65) |
|
|
|
14 |
(58) |
5 |
(36) |
9 |
(14) |
|
|
|
| negative | 10 | (37) | 7 | (70) | 3 | (30) | 0.09 | 0.23 | (0.04–1.25) | 10 | (42) | 10 | (100) | 0 | (0) | 0.001 | ||
Φ: Histopathologically, the gross pathologic types were different for ESCC and GCA, in ESCC, 1: medullary; 2: fungating; 3: ulcerating; 4: constriction & intraluminal; in GCA, 1: protruding; 2: ulcerating; 3: infiltrating.
▲: Not detected.